FREE-005
Undisclosed
PreclinicalActive
Key Facts
About Freedom Biosciences
Freedom Biosciences is a private, preclinical-stage biotech founded in 2021, headquartered in Boston, USA. The company is built upon the pioneering ketamine research of its co-founder, Dr. John Krystal, and aims to develop next-generation, ketamine-based and combination neuropsychiatric drugs. Its pipeline includes programs targeting treatment-resistant depression and comorbid conditions, with a core strategy of improving upon the first-generation therapies like esketamine. The company is led by CEO Dina Burkitbayeva and combines deep scientific expertise with venture investment experience in the psychedelics sector.
View full company profileTherapeutic Areas
Other Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| Preclinical ISAC 1 | Bolt Biotherapeutics | Preclinical |
| Preclinical ISAC 2 | Bolt Biotherapeutics | Preclinical |
| ART12.11 | Artelo Biosciences | Preclinical |
| Novel Vaccines | MSD | Development |
| SLS-009 | Seelos Therapeutics | Discovery |
| Technosphere Platform (New Formulations) | MannKind | Discovery/Preclinical |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |
| Internal sdAb Discovery Program | NanoTag Biotechnologies | Discovery |
| NB-701 | Nerai Biosciences | Discovery |
| Undisclosed Therapeutic Program(s) | Bright Cell | Clinical Trial (Phase unspecified) |
| Biosimilars Pipeline | Intelligent Therapeutics | Pre-clinical/Development |
| Proprietary Therapeutic Pipeline | Excelsior Sciences | Discovery |